A phase 3 trial, the SAFFRON trial (NCT05261399), is underway to compare savolitinib and Osimertinib combination therapy with platinum-based double chemotherapy in patients with disease-induced NSCLC (EGFR mutation, MET overexpression, and/or MET gene amplification) after Osimertinib treatment. This evidence concerns the gene MET and non-small cell lung carcinoma.